Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, the U.S. Food and Drug Administration (FDA) approved new therapies, rates of anal cancer are on the rise, and more.
A new analysis observed a significant increase in the incidence of and mortality associated with squamous cell carcinoma of the anus.
Radiation exposure from computed tomography scans is associated with an increased risk of thyroid cancer and leukemia, according to a study published in JNCI Cancer Spectrum.
Imprisoned women are at higher risk of cervical cancer and HPV infection than the general population, according to a study published in the Journal of Epidemiology & Community Health.
Patients with metastatic non-small cell lung cancer may not have access to certain high-cost agents depending on where they live and where they receive treatment, according to a new report.
The FDA approved Brukinsa™ (zanubrutinib) capsules for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.
In case you missed it, more hem/onc headlines are featured below:
- FDA Approves First Targeted Treatment for Sickle Cell Crisis
- Classifying Pancreatic Cancer Tumors May Improve Treatment Options
- One-Third of Patients Not Receiving Enough Information on Treatment-Related Adverse Events
- Platinum Exposure May Increase Mortality Risk in Testicular Cancer Patients
- Oncologists Hesitant to Discuss Fertility